Ionis Pharmaceuticals, Inc.


Ionis Pharmaceuticals is dedicated to unlocking the potential of RNA- and DNA-targeted medicines to improve human health. With a history of pioneering science and technology, Ionis aims to develop innovative therapies for serious diseases across various focus areas including neurology, cardiology, and high unmet patient needs. The company emphasizes responsible operation, diversity, inclusion, and community support, striving to create a healthier and more resilient future for all.

Industries

biotechnology
health-care
medical
pharmaceutical

Nr. of Employees

large (251-1000)

Ionis Pharmaceuticals, Inc.

Carlsbad, California, United States, North America


Products

Pipeline of RNA- and DNA-targeted therapeutic candidates

A portfolio of investigational RNA- and DNA-targeted medicines in development across neurology, cardiology and select high-need areas (rare diseases, metabolic and renal indications).

Commercialized RNA-targeted therapy for a cardiometabolic indication

A marketed RNA-targeted medicine for a rare cardiometabolic disease that has undergone regulatory review and independent commercial launch preparations.


Services

Competitive research funding program for disruptive therapeutics

A program to fund high-risk/high-reward academic projects to accelerate novel therapeutic technologies, including award administration and IP licensing terms.

Clinical trial conduct and development support

Design and execution of clinical studies across multiple therapeutic areas and phases, including pivotal trials and data publication.

Supplier onboarding and procure-to-pay services

Electronic supplier portal onboarding, purchase order management, electronic invoicing (cXML/Actionable Email) and payment processing support for vendors.

Patient grants and sponsorships

Grant and sponsorship programs to support patient community initiatives, disease awareness, education and patient resources.

Expertise Areas

  • RNA and DNA therapeutics development
  • Antisense oligonucleotide (ASO) design
  • siRNA therapeutics
  • Gene editing research
  • Show More (7)

Key Technologies

  • Antisense oligonucleotides (ASOs)
  • siRNA
  • Gene editing methods
  • Modified oligonucleotide backbones (e.g., MsPA)
  • Show More (6)

Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.